



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

**NASDAQ: CELG**

Last Trade:	85.69
Trade Time:	4:00 PM ET Jul 13, 2018
Change:	0.09 (0.105%)
Day Range	85.24 - 86.05
52-Week Range	74.13 - 147.17
Volume	4,617,355

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

*Jul 10, 2018*  
[Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study](#)

*Jul 9, 2018*  
[Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia](#)

*Jul 2, 2018*  
[Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018](#)

*Jun 28, 2018*  
[Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes](#)

*Jun 19, 2018*  
[Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi](#)

**Upcoming Events** [\[ View all \]](#)

*Jul 26, 2018 9:00 AM ET*  
[Celgene Corporation Q2 2018 Earnings Conference Call](#)

**Events** [\[ View all \]](#)

**Financials** [\[ View all \]](#)

*Feb 7, 2018*  
[Annual Report \(10-K\)](#)

*Apr 30, 2018*  
[Proxy Statement \(DEF 14A\)](#)

*May 4, 2018*  
[Quarterly Report \(10-Q\)](#)

*Oct 26, 2017*  
[Quarterly Report \(10-Q\)](#)

*Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)

